Floatz logo

Spk-8016

Blood Coagulation Disease

Spark Therapeutics, Inc.gene_therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Blood Coagulation Disease cohort.

Asset / SponsorPhaseRating
Kcentra
CSL Behring
Phase 3BB
Factor Ix
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3BB
Beriplex® P/N
CSL Behring
Phase 3BB
Rifaximin
University of Roma La Sapienza
Phase 4B
Fresh Frozen Plasma
CSL Behring
Phase 3B

View all 10 →

Same molecule, other indications

Spk-8016 is also rated in:

inherited blood coagulation disorderDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
disease of genetic or genomic mechanismDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
X-linked diseaseDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →